American Academy of Dermatology

The development and implementation of quality improvement (QI) programs can positively impact patient care and outcomes. As such, it behooves physicians to research and implement QI practice initiatives and measures in their practice.

Dermatologists are expanding their skill sets and exploring new techniques to enable gender-diverse patients to achieve their medical and aesthetic goals.

Experts present detailed guidelines on how to diagnose and treat common skin diseases and conditions in the Asian American population.

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases.

New regulations, latest absorption data, and updates on environmental and health impacts are shaping the world of photoprotection.

Trichoscopy, which is based on dermoscopy, can be a valuable tool for diagnosing conditions that cause hair loss and inflammatory scalp disease.

Dermatologists are divided over concerns of spironolactone being underused in women and patients taking isotretinoin being overmonitored.

In this episode, we take a look back at what happened at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), including exclusive interviews with two KOLs about their presentations regarding climate change and new data on biologics for psoriasis.

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.

In part two of our interview with Misha Rosenbach, MD, he reveals what kind of skin manifestations are on the rise due to global warming and how dermatologists can help fight against climate change.

Misha Rosenbach, MD, discusses the effects climate change has on dermatology and how using social media can help spread awareness.

A study at AAD VMX 2021 presented data on possible association between sex, skin cancer medication, and dermatologic adverse events.

New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).

A study presented at the American Academy of Dermatology Virtual Meeting Experience 2021 exhibited new safety and efficacy data for etrasimod as a potential treatment for atopic dermatitis.

Mark Lebwohl, MD, discusses his recent presentation from AAD VMX 2021 regarding new data for various biologics for the treatment of psoriasis.

According to study data recently presented at AAD VMX 2021, tofacitinib demonstrated positive results when being evaluated as a possible treatment for cutaneous sarcoidosis.

Interim analysis of data from the ECZTEND study evaluating the long-term safety, efficacy, and tolerability of tralokinumab for treatment of atopic dermatitis was presented at AAD VMX 2021.

Catch up on all of the latest news coming out of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021).

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.

Deucravacitinib meets primary end points for treating moderate to severe psoriasis.

Revance presents 4 AAD VMX ePoster abstracts examining phase 3 study data for DAXI, and the impact of HA filler manufacturing technologies on HA chain degradation.

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

A survey found a large proportion of dermatologists surveyed said their patients referenced video conferencing as the reason for seeking cosmetic consultation since the start of the pandemic.

In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

The American Academy of Dermatology Announced the results from its annual election, with 2 officers and 4 board members assuming their new positions in March 2022.